Gene Therapy
Cell and gene therapies require precision control systems to deliver safe and effective treatments to patients.
Precise fine-tuned control
Enabling the next generation of gene therapies
Safety remains a major concern in gene therapies and the FDA has indicated that in the future, safety systems such as gene control systems will become a necessity.
Naturally occurring genetic systems are highly responsive to the environments that they’re in. The current generation of gene therapies lacks this responsiveness, meaning that they are more of a “sledgehammer” approach rather than a fine-tuned intervention.
For many conditions, an over- or under-production of a certain protein can cause two distinct diseases. To treat these diseases with gene therapies, the therapeutics need to be made responsive to their own activity to stay within safe bounds.
RNA-level control allows for much more precise control of gene therapy activity, allowing side effects to be more effectively mitigated and expanding the potential application of these therapies.
Concinnity’s approach
Highly modular RNA control systems
Our platform uses cutting-edge AI and synthetic biology expertise to design unique RNA-based systems that enable the precise control of gene therapies even after dosing, conveying the ability to respond to and reduce their own side effects.
By reducing the risk profile of gene therapies, our approach will expand the range of diseases that can be treated, benefitting a wider group of patients.
Realise a new era in gene therapy
Partner with Concinnity to enhance the safety and expand the applications of your gene therapies.